These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
719 related items for PubMed ID: 29650420
1. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420 [Abstract] [Full Text] [Related]
2. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP. Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746 [Abstract] [Full Text] [Related]
3. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence? Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, Franchi A, Capanna R, Campanacci DA. Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015 [Abstract] [Full Text] [Related]
4. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T. J Orthop Surg (Hong Kong); 2020 Sep; 28(2):2309499020929786. PubMed ID: 32539628 [Abstract] [Full Text] [Related]
5. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS. Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001 [Abstract] [Full Text] [Related]
6. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab. Chinder PS, Hindiskere S, Doddarangappa S, Pal U. Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058 [Abstract] [Full Text] [Related]
7. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134 [Abstract] [Full Text] [Related]
8. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone. Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC. Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217 [Abstract] [Full Text] [Related]
9. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study. Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T. BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567 [Abstract] [Full Text] [Related]
10. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T. World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488 [Abstract] [Full Text] [Related]
11. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. von Borstel D, A Taguibao R, A Strle N, E Burns J. Skeletal Radiol; 2017 Apr 08; 46(4):571-578. PubMed ID: 28188337 [Abstract] [Full Text] [Related]
12. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience. Agarwal MG, Gundavda MK, Gupta R, Reddy R. Clin Orthop Relat Res; 2018 Sep 08; 476(9):1773-1782. PubMed ID: 30794215 [Abstract] [Full Text] [Related]
13. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Lipplaa A, Dijkstra S, Gelderblom H. Curr Opin Oncol; 2019 Jul 08; 31(4):329-335. PubMed ID: 30844887 [Abstract] [Full Text] [Related]
14. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. Borkowska A, Goryń T, Pieńkowski A, Wągrodzki M, Jagiełło-Wieczorek E, Rogala P, Szacht M, Rutkowski P. Oncol Lett; 2016 Dec 08; 12(6):4312-4318. PubMed ID: 28101196 [Abstract] [Full Text] [Related]
15. Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. Boye K, Jebsen NL, Zaikova O, Knobel H, Løndalen AM, Trovik CS, Monge OR, Hall KS. Acta Oncol; 2017 Mar 08; 56(3):479-483. PubMed ID: 28105885 [Abstract] [Full Text] [Related]
16. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone. Puri A, Gulia A, Hegde P, Verma V, Rekhi B. Bone Joint J; 2019 Feb 08; 101-B(2):170-177. PubMed ID: 30700112 [Abstract] [Full Text] [Related]
17. Recommencement of Denosumab for Unresectable Giant Cell Tumor of the Cervical Spine: A Case Report. Law GW, Yeo NEM, Howe TS, Tan YZ, Tan SB, Siddiqui MMA. Spine (Phila Pa 1976); 2018 May 01; 43(9):E551-E556. PubMed ID: 29016442 [Abstract] [Full Text] [Related]
18. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center. Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W. J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187 [Abstract] [Full Text] [Related]